EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity



Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity



Toxicology Letters (Shannon) 82-83(SPEC ISSUE): 419-424



Over the past 5 years or so, much attention has been given to the possible use of synthetic antisense oligonucleotide analogs as a new class of therapeutic agents that function by sequence-specific inhibition of genetic expression. The basic design concepts which underline this novel approach to drug discovery are briefly described herein, together with some of the chemical, biochemical, and pharmacological aspects of phosphorothioate oligodeoxynucleotides that are first-generation antisense compounds now under clinical investigation. Possible molecular mechanisms of toxicity for this class, and other structural types of antisense compounds are discussed with the hope of stimulating interest in future toxicological studies in this emerging area of drug development.

Accession: 009770898

Download citation: RISBibTeXText

PMID: 8597087

DOI: 10.1016/0378-4274(95)03571-0

Download PDF Full Text: Antisense phosphorothioate oligodeoxynucleotides: Introductory concepts and possible molecular mechanisms of toxicity



Related references

End-capped antisense oligodeoxynucleotides effectively inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Molecular Brain Research. 47(1-2): 223-228, 1997

The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucleic Acids Research 18(7): 1763-1769, 1990

Separation of phosphodiester oligodeoxynucleotides and phosphorothioate antisense oligodeoxynucleotides by capillary zone electrophoresis at low pH. Se Pu 25(1): 101-106, 2007

Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. Journal of Investigative Dermatology 104(5): 813-818, 1995

Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha and antisense bcl-2 phosphorothioate oligodeoxynucleotides Relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Molecular Pharmacology 60(6): 1296-1307, December, 2001

Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Current Opinion in Investigational Drugs 2(4): 562-573, 2001

Exploiting the potential of antisense: beyond phosphorothioate oligodeoxynucleotides. Chemistry & Biology 3(5): 319-323, 1996

Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?. Antisense Research and Development 5(4): 241-241, 1995

Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends in Biotechnology 14(5): 147-149, 1996

Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Molecular Pharmacology 60(6): 1296-1307, 2001

A perspective on the use of phosphorothioate antisense oligodeoxynucleotides for therapeutic applications. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 656-657, 1995

Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism. Journal of the National Cancer Institute 88(7): 391-393, 1996

Downregulation of androgen receptor expression by antisense phosphorothioate oligodeoxynucleotides. Proceedings of the American Association for Cancer Research Annual Meeting 39: 13, March, 1998

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Research 28(2): 582-592, 1999